Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells

Citation
I. Laketic-ljubojevic et al., Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells, BONE, 25(6), 1999, pp. 631-637
Citations number
38
Categorie Soggetti
Endocrynology, Metabolism & Nutrition","da verificare
Journal title
BONE
ISSN journal
87563282 → ACNP
Volume
25
Issue
6
Year of publication
1999
Pages
631 - 637
Database
ISI
SICI code
8756-3282(199912)25:6<631:FCONAC>2.0.ZU;2-F
Abstract
Our recent identification of glutamate receptors in bone cells suggested a novel means of paracrine communication in the skeleton. To determine whethe r these receptors are functional, we investigated the effects of the excita tory amino acid, glutamate, and the pharmacological ligand, N-methyl-D-aspa rtic acid (NMDA), on glutamate like receptors in the human osteoblastic cel l lines MG63 and SaOS-2, Glutamate binds to osteoblasts, with a K-d of appr oximately 10(-4) mol/L and the NMDA receptor antagonist, DL-2-amino-5-phosp honovaleric acid (D-APV), inhibits binding. Using the patch-clamp technique , we measured whole-cell currents before and after addition of L-glutamate or NMDA and investigated the effects of the NMDA channel blockers, dizolcip ine maleate (MK801), and Mg2+, and the competitive NMDA receptor antagonist , 3-((R)-2-carboxypiperazin-4-yl)-propyl-1 phosphoric acid (R-CPP), on agon ist-induced currents. Both glutamate and NMDA induced significant increases in membrane currents. Application of Mg2+ (200 mu mol/L) and MK801 (100 mu mol/L) caused a significant decrease in inward currents elicited in respon se to agonist stimulation. The competitive NMDA receptor antagonist, R-CPP (100 mu mol/L), also partially blocked the NMDA-induced currents in MG63 ce lls. This effect was reversed by addition of further NMDA (100 mu mol/L). I n Pura-2-loaded osteoblasts, glutamate induced elevation of intracellular f ree calcium, which was blocked by MK801, These results support the hypothes is that glutamate plays a role in bone cell signaling and suggest a possibl e role for glutamate agonists/antagonists in the treatment of bone diseases . (C) 1999 by Elsevier Science Inc. All rights reserved.